pegfilgrastim

Pegfilgrastim
Systematic (IUPAC) name
	N-(3-Hydroxypropyl)Methionylcolony-stimulating Factor (human), 1-Ether with .Alpha.-Methyl-.Omega.-Hydroxypoly(Oxyethylene)
Clinical data
Trade names	Neulasta
AHFS/Drugs.com	monograph
MedlinePlus	a607058
Pregnancy cat.	C (US)
Legal status	℞-only (US)
Pharmacokinetic data
Half-life	15-80 hrs
Identifiers
CAS number	208265-92-3
ATC code	L03AA13
DrugBank	DB00019
UNII	3A58010674
KEGG	D06889
ChEMBL	CHEMBL1201568
Chemical data
Formula	C845H1343N223O243S9 + PEG
Mol. mass	39000 g/mol
(what is this?) (verify)

ペグフィルグラスチム

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/04/20 22:19:56」(JST)

wiki en

[Wiki en表示]

Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. It serves to stimulate the level of white blood cells (neutrophils).^[1]

Amgen manufactures pegfilgrastim under the brand name Neulasta, which was mainly worked on by Martine Allard, while Roche manufactures it under the name Neulastim. In India it is also marketed by Abbott Healthcare under the brand name Imupeg. The drug is prepared by coupling a 20 kDa polyethylene glycol (PEG) molecule to the N-terminus of the filgrastim protein. Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours).^[2]^[3]

Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy.^[3]

References

^ Walsh, G, Spada, S. "Epogen/Procrit" in: Directory of approved biopharmaceutical products. CRC Press, 2005, pp. 136-137.
^ Ho, R.J.Y., Gibaldi, M. Biotechnology and biopharmaceuticals: transforming proteins and genes into drugs Wiley-IEEE, 2003, p. 139, 158.
^ ^a ^b Drugs.com: Pegfilgrastim

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 化学療法による好中球減少症を有する患者における顆粒球コロニー刺激因子の利用 use of granulocyte colony stimulating factors in patients with chemotherapy induced neutropenia
2. 幹細胞および前駆細胞の動員における組換え造血成長因子の使用 use of recombinant hematopoietic growth factors in stem cell and progenitor cell mobilization
3. 骨髄異形成症候群の合併症の管理 management of the complications of the myelodysplastic syndromes
4. 成人における放射線障害の治療 treatment of radiation injury in the adult
5. 化学療法により好中球減少を起こした高リスクな成人への感染症予防 prophylaxis of infection during chemotherapy induced neutropenia in high risk adults

English Journal

Retrospective Analysis of Relative Dose Intensity in Patients With Non-Hodgkin Lymphoma Receiving CHOP-based Chemotherapy and Pegfilgrastim.

Balducci L1, Mo M, Abella E, Saven A.
American journal of clinical oncology.Am J Clin Oncol.2014 Dec;37(6):603-10. doi: 10.1097/COC.0000000000000141.
OBJECTIVES: To evaluate primary prophylaxis with pegfilgrastim, a recombinant human granulocyte colony-stimulating factor, on maintaining relative dose intensity (RDI) in patients with non-Hodgkin lymphoma (NHL) receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-ritu
PMID 25350463

Lipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteers.

Buchner A1, Lammerich A, Abdolzade-Bavil A, Müller U, Bias P.
Current medical research and opinion.Curr Med Res Opin.2014 Dec;30(12):2523-33. doi: 10.1185/03007995.2014.962131. Epub 2014 Sep 25.
Abstract Objective: Two phase I, single-blind (subject blinded to treatment), randomized studies were conducted to assess the pharmacodynamics, pharmacokinetics, safety, and tolerability of lipegfilgrastim compared with pegfilgrastim in healthy adult volunteers.METHODS: Study 1 consisted of a pilot
PMID 25251999

A modified filgrastim regimen does not reduce pain burden compared to pegfilgrastim in women receiving chemotherapy for non-metastatic breast cancer.

Leung M1, Florendo J, Kano J, Marr-Del Monte T, Higgins B, Myers R, Menon T, Jones G.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.Support Care Cancer.2014 Nov 26. [Epub ahead of print]
PURPOSE: The short half-life of filgrastim allows for modification in the dose or duration of prophylaxis to limit inconvenience, adverse effects, and cost. The objectives of this study were to characterize and compare pain and neutropenic events between filgrastim and pegfilgrastim.METHODS: A prosp
PMID 25421443